In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Group

www.ucb-group.com

Latest From UCB Group

Boehringer Doubles Down On Deafness With Rinri Backing

After making a move into hearing loss with an investment into Acousia Therapeutics, BI is backing a UK biotech which hopes to reverse neuropathic sensorineural hearing loss.

Ear, Nose & Throat StartUps and SMEs

Novartis Settles Short-Lived Suit Over Janssen's Psoriasis Drug Promo

The companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating.
Legal Issues Immune Disorders

Novartis Settles Short-Lived Suit Over Janssen's Psoriasis Drug Promo

Companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating. 
Advertising, Marketing & Sales Legal Issues

Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes

Taltz has sailed through the latest trial in Lilly’s COAST program, in non-radiographic axial spondyloarthritis, but choppy waters may be ahead; meanwhile, Lilly signs an immunology deal with Avidity Biosciences.

Clinical Trials Inflammation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register